Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | GRK5 | P34947 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1396143 | 0.98 | ABL1 (0.39) | ABL1DAPK3JAK2PRKD3MAP4K4 | |
| SCHEMBL15558646 | 0.81 | LMNA (0.46) | ALDH1A1KDM4EHSD17B10HPGDGAA | |
| SCHEMBL17700915 | 0.79 | KDM4E (0.45) | ABL1DAPK3JAK2PRKD3MAP4K4 | |
| SCHEMBL2446096 | 0.79 | DAPK3 (0.41) | ABL1DAPK3JAK2PRKD3MAP4K4 | |
| SCHEMBL13731286 | 0.78 | DAPK3 (0.40) | ABL1DAPK3JAK2PRKD3MAP4K4 | |
| SCHEMBL15558130 | 0.76 | LMNA (0.36) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL13505847 | 0.76 | ALDH1A1 (0.35) | ALDH1A1KDM4EHSD17B10CASP1TSHR | |
| SCHEMBL16007041 | 0.75 | TSHR (0.36) | ABL1DAPK3JAK2PRKD3MAP4K4 | |
| SCHEMBL17700838 | 0.75 | MAPK14 (0.38) | ABL1DAPK3JAK2PRKD3MAP4K4 | |
| Ethane SCHEMBL15559374 | 0.75 | ABL1 (0.38) | ABL1DAPK3JAK2PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624043-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250163063-A1 | INHIBITORS OF CDK4/6 KINASE | KHORA SPV 1, LLC | 2025-05-22 | — | — | US | disclosed |
| EP-4469062-A1 | INHIBITORS OF CDK4/6 KINASE | Kinnate Biopharma Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-119013030-A | Inhibitors of CDK4/6 kinase | 金耐特生物制药公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240317757-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2024-09-26 | — | — | US | disclosed |
| US-11827642-B2 | Compositions useful for treating disorders related to KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827642-B2 | Compositions useful for treating disorders related to KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827642-B2 | Compositions useful for treating disorders related to KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11753413-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753413-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-12 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-7030118-B2 | Pyrrolotriazinone compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| WO-2006004636-A2 | FUSED HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004833-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
| EP-1519729-A1 | PYRROLOTRIAZINONE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003099286-A1 | PYRROLOTRIAZINONE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | ABL1 3/4885DAPK3 134/4885JAK2 54/4885 |
| US-20240317757-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, MSH2 | ABL1 539/4885DAPK3 3834/4885JAK2 2552/4885 |
| US-12624043-B2 | Compositions useful for treating disorders related to kit | KIT, RET, SLC26A4 | ABL1 387/4885DAPK3 4612/4885JAK2 312/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | ABL1 68/4885DAPK3 123/4885JAK2 60/4885 |
| US-11753413-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | ABL1 15/4885DAPK3 571/4885JAK2 1/4885 |
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | CCNB1, NUMA1, CCNA1 | ABL1 400/4885DAPK3 1508/4885JAK2 1924/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | ABL1 3/4885DAPK3 134/4885JAK2 54/4885 |
| US-20250163063-A1 | INHIBITORS OF CDK4/6 KINASE | CDK4, CDK6, CDK2 | ABL1 163/4885DAPK3 263/4885JAK2 181/4885 |
| US-11827642-B2 | Compositions useful for treating disorders related to KIT | KIT, APC, MSH2 | ABL1 539/4885DAPK3 3834/4885JAK2 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.